Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.

doi:10.1097/JTO.0b013e31822eeba2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2012

Azuma Koichi, Okamoto Isamu, Kawahara Akihiko, Taira Tomoki, Nakashima Kazutaka, Hattori Satoshi, Kinoshita Takashi, Takeda Masayuki, Nakagawa Kazuhiko, Takamori Shinzo, Kuwano Michihiko, Ono Mayumi, Kage Masayoshi

Abstract excerpt

INTRODUCTION: Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with an increased response to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib in patients with non-small cell lung cancer (NSCLC). Although most NSCLC patients with EGFR mutations benefit from EGFR-TKI treatment, the efficacy of such treatment varies among individuals. Molecular markers for prediction of...

Topics

Aged
Aged, 80 and over
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Disease-Free Survival
ErbB Receptors
Female
Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Humans

Immunohistochemistry

Kaplan-Meier Estimate

Lung Neoplasms

Male

Middle Aged

Mutation

Proportional Hazards Models

Protein Kinase Inhibitors

Quinazolines

Source

Open in PubMed

Identifiers

PMID: 21892099
DOI: 10.1097/JTO.0b013e31822eeba2

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-21892099-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.PMID 21892099Read ↗

Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.Semantic proximity Read ↗

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative RecurrenceSemantic proximity Read ↗

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung CancerSemantic proximity Read ↗

Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.Semantic proximity Read ↗

Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.Semantic proximity Read ↗

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With GefitinibSemantic proximity Read ↗

The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer.Semantic proximity Read ↗

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Semantic proximity Read ↗

microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.Semantic proximity Read ↗

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.Semantic proximity Read ↗

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.Semantic proximity Read ↗

E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.